In the MET-high copy number and IHC 3+ models, ABN401 significantly suppressed tumor growth, increasing TGI from 99.11% to 109.1% at a dose of 30 mg/kg, as shown in Figure 3D–F and Table 1, whereas in the moderate MET copy number models, ABN401 did not inhibit tumor growth, as shown in Figure 3H–K and Table 1. Here, MET is linked to neoplasm.